eMedicine Specialties > Dermatology > Pediatric Diseases

Ichthyosis Fetalis

Author: Julie Prendiville, MB, BCh, Clinical Professor in Pediatrics, University of British Columbia; Head, Division of Pediatric Dermatology, British Columbia's Children's Hospital, Canada
Contributor Information and Disclosures

Updated: Oct 21, 2008

Introduction

Background

Ichthyosis fetalis, also known as harlequin ichthyosis (HI), is the most severe form of congenital ichthyosis. It is characterized by a profound thickening of the keratin layer in fetal skin. The affected neonate is born with a massive, horny shell of dense, platelike scale and contraction abnormalities of the eyes, ears, mouth, and appendages. This armor limits movement and compromises the protective skin barrier, leaving the newborn susceptible to metabolic abnormalities and infection.

The term harlequin derives from the newborn's facial expression and the triangular and diamond-shaped pattern of hyperkeratosis. The newborn's mouth is pulled wide open, mimicking a clown's smile.

The underlying genetic abnormality in ichthyosis fetalis has been identified as a mutation in the lipid-transporter gene ABCA12 on chromosome 2. The presence of homozygous mutations in affected individuals supports an autosomal recessive pattern of inheritance.

Immunohistocytochemical examination of the skin reveals characteristic abnormalities in the structure of lamellar granules and in the expression of epidermal keratin.

In the past, ichthyosis fetalis was uniformly fatal. Improved survival has been achieved with intense supportive care and systemic retinoid therapy in the neonatal period. Patients who survive manifest a debilitating, persistent ichthyosis similar to other autosomal recessive ichthyoses, such as lamellar ichthyosis (LI) or nonbullous congenital ichthyosiform erythroderma.1,2

Other eMedicine articles on ichthyosis include the following:

Pathophysiology

This disease primarily affects the skin. Other systems are significantly compromised by the hyperkeratosis and concomitant deformities. Neonates are often born prematurely.

Marked eclabium and ectropion is present secondary to the taut, unyielding skin. The ears may be absent or poorly developed. The arms, feet, and digits have flexion contractures and may be hypoplastic. The skin barrier is severely compromised, leading to excessive water loss, electrolyte abnormalities, temperature dysregulation, and an increased risk of life-threatening infection. The tight, armorlike scale can restrict respiration. Poor feeding and impaired intestinal absorption are common.

Frequency

International

More than 100 cases have been reported.

Mortality/Morbidity

The mortality rate is high. With neonatal intensive care and the advent of retinoid therapy, some babies have survived the newborn period. They are still at risk of dying from systemic infection, which is the most common cause of death.

Race

No racial predilection is known.

Sex

No increased risk based on sex is known.

Clinical

History

This condition manifests at birth. It may or may not have been diagnosed prenatally in a high-risk family. The history should carefully explore the following questions:

  • Is the couple consanguineous?
  • Does the couple have another child with ichthyosis?
  • Does the family have a history of severe skin disorders?
  • Do the parents or family members have a history of intrauterine or neonatal death?
  • What was the expected date of delivery?
  • Were decreased fetal movements or intrauterine growth retardation noted during the pregnancy?
  • Did the mother undergo prenatal ultrasonography?
  • Were prenatal procedures (eg, amniocentesis, fetal skin biopsy) performed?

Physical

  • Skin: Severely thickened skin with large, shiny plates of hyperkeratotic scale is present at birth. Deep, erythematous fissures separate the scales.
  • Eyes: Severe ectropion is present. The free edges of the upper and lower eyelids are everted, leaving the conjunctivae at risk for desiccation and trauma.
  • Ears: The pinnae may be small and rudimentary or absent.
  • Lips: Severe traction on the lips causes eclabium and a fixed, open mouth. This may result in feeding difficulties.
  • Nose: Nasal hypoplasia and eroded nasal alae may occur.
  • Extremities
    • The limbs are encased in the thick, hyperkeratotic skin, resulting in flexion contractures of the arms, the legs, and the digits. Limb motility is poor to absent. Circumferential constriction of a limb can occur, leading to distal swelling or even gangrene.
    • Hypoplasia of the fingers, toes, and fingernails is reported. Polydactyly is described.
  • Temperature dysregulation
    • Thickened skin prevents normal sweat gland function and heat loss.
    • The infants are heat intolerant and can become hyperthermic.
  • Respiratory status: Restriction of chest-wall expansion can result in respiratory distress, hypoventilation, and respiratory failure.
  • Hydration status: Dehydration from excess water loss can cause tachycardia and poor urine output.
  • Central nervous system
    • Metabolic abnormalities can cause seizures. CNS depression can be a sign of sepsis or hypoxia.
    • Hyperkeratosis may restrict spontaneous movements, making neurologic assessment difficult.

Causes

  • Genetic factors
    • Mutations in a gene known as ABCA12 (adenosine triphosphate [ATP]-binding cassette transporter, subfamily A, member 12), in chromosome region 2q35, underlie this disorder.3,4 Patients with HI are usually homozygous for this mutation consistent with autosomal recessive inheritance.
    • The ABC superfamily of genes encodes proteins that transport a number of substrates across cell membranes.5 ABCA12 is thought to encode a transmembrane protein that mediates lipid transport.
    • This ABCA12 -mediated lipid-transfer system is thought to be essential to the transfer of lipids from the cytosol of the corneocyte into lamellar granules. Lamellar granules are intracellular granules that originate from the Golgi apparatus of keratinocytes in the stratum corneum. These granules are responsible for secreting lipids that maintain the skin barrier at the interface between the granular cell layer and the cornified layer. The extruded lipids are arranged into lamellae in the intercellular space with the help of concomitantly released hydrolytic enzymes. The lamellae form the skin's hydrophobic sphingolipid seal.
    • In ichthyosis fetalis, the ABCA12 -mediated transfer of lipid to lamellar granules is absent. The lamellar granules themselves are morphologically abnormal or absent. Normal extrusion of lipid from these granules into the intercellular space cannot occur, and lipid lamellae are not formed. This defective lipid "mortar" between corneocyte "bricks" results in aberrant skin permeability and lack of normal corneocyte desquamation.
    • The exact mechanism of this transport abnormality has yet to be elucidated. One hypothesis involves abnormal calcium-mediated signaling by means of calpains. Calpains are calcium-activated neutral proteases that are essential to normal epidermal differentiation. Calpains are consistently underexpressed in patients with HI compared with the general population.6
    • The pivotal role of ABCA12 in HI is supported by in vitro data. Studies have demonstrated normalization of lipid transport when the wild-type ABCA12 gene is transferred to keratinocytes of patients with HI.7
    • A milder form of ichthyosis, lamellar ichthyosis type 2 (LI-2), also involves mutations in the ABCA12 gene. The phenotypic difference between the disorders has been explained on the basis of differing genotypic variants. Nonsense mutations in ABCA12 are seen in ichthyosis fetalis, whereas missense mutations underlie LI-2.
    • Other chromosomal abnormalities are described in association with HI. One patient with a de novo deletion of chromosome arm 18q has been reported.8
    • The Medscape Genomic Medicine Resource Center may be of interest.
  • Histologic, ultrastructural, and biochemical factors
    • Histologic, ultrastructural, and biochemical studies have identified several characteristic abnormalities in the skin of patients with ichthyosis fetalis.
    • The 2 main abnormalities involve lamellar granules and the structural proteins of the cell cytoskeleton. The relationship between the HI gene ABCA12 and abnormal lamellar granules is well documented. The pathophysiology of the other abnormalities documented below has yet to be elucidated.
  • Abnormal lamellar granule structure and function
    • The pivotal role of lamellar granules in maintaining a normal skin barrier is described in the Genetic factors bullet points at the beginning of this section.
    • All patients with ichthyosis fetalis have absent or defective lamellar granules and no intercellular lipid lamellae. The lipid abnormality is believed to allow excessive transepidermal water loss. Lack of released hydrolases prevents desquamation, resulting in a severe retention hyperkeratosis.
  • Abnormal conversion of profilaggrin to filaggrin
    • Profilaggrin is a phosphorylated polyprotein residing in keratohyalin granules in keratinocytes in the granular cell layer. During the evolution to the corneal layer, profilaggrin converts to filaggrin by means of dephosphorylation. Filaggrin allows dense packing of keratin filaments. Its subsequent breakdown into amino acids occurs prior to desquamation of the stratum corneum.
    • Some patients with HI have a persistence of profilaggrin and an absence of filaggrin in the stratum corneum. A defect in protein phosphatase activity and subsequent lack of conversion of profilaggrin to filaggrin is hypothesized.
  • Abnormal expression of keratin
    • Keratinocyte cell cultures have yielded interesting and heterogeneous findings among patients with ichthyosis fetalis.
    • Keratin filament density is low in most patients. Expression of certain keratins is abnormal in some patients and normal in others. How this altered expression of structural proteins influences desquamation is uncertain.
  • Abnormal keratohyalin granules
    • Keratohyalin granules are identified by antifilaggrin antibodies and can be abnormal in some patients with ichthyosis fetalis.
    • They can be large and stellate, small and rounded, or absent.

More on Ichthyosis Fetalis

Overview: Ichthyosis Fetalis
Differential Diagnoses & Workup: Ichthyosis Fetalis
Treatment & Medication: Ichthyosis Fetalis
Follow-up: Ichthyosis Fetalis
Multimedia: Ichthyosis Fetalis
References

References

  1. Haftek M, Cambazard F, Dhouailly D, Réano A, Simon M, Lachaux A, et al. A longitudinal study of a harlequin infant presenting clinically as non-bullous congenital ichthyosiform erythroderma. Br J Dermatol. Sep 1996;135(3):448-53. [Medline].

  2. Lawlor F. Progress of a harlequin fetus to nonbullous ichthyosiform erythroderma. Pediatrics. Dec 1988;82(6):870-3. [Medline].

  3. Kelsell DP, Norgett EE, Unsworth H, Teh MT, Cullup T, Mein CA, et al. Mutations in ABCA12 underlie the severe congenital skin disease harlequin ichthyosis. Am J Hum Genet. May 2005;76(5):794-803. [Medline].

  4. Lefévre C, Audebert S, Jobard F, Bouadjar B, Lakhdar H, Boughdene-Stambouli O, et al. Mutations in the transporter ABCA12 are associated with lamellar ichthyosis type 2. Hum Mol Genet. Sep 15 2003;12(18):2369-78. [Medline].

  5. Uitto J. The gene family of ABC transporters--novel mutations, new phenotypes. Trends Mol Med. Aug 2005;11(8):341-3. [Medline].

  6. Michel M, Fleckman P, Smith LT, Dale BA. The calcium-activated neutral protease calpain I is present in normal foetal skin and is decreased in neonatal harlequin ichthyosis. Br J Dermatol. Dec 1999;141(6):1017-26. [Medline].

  7. Akiyama M, Sugiyama-Nakagiri Y, Sakai K, McMillan JR, Goto M, Arita K, et al. Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. J Clin Invest. Jul 2005;115(7):1777-84. [Medline].

  8. Stewart H, Smith PT, Gaunt L, Moore L, Tarpey P, Andrew S, et al. De novo deletion of chromosome 18q in a baby with harlequin ichthyosis. Am J Med Genet. Sep 1 2001;102(4):342-5. [Medline].

  9. Akiyama M, Dale BA, Smith LT, Shimizu H, Holbrook KA. Regional difference in expression of characteristic abnormality of harlequin ichthyosis in affected fetuses. Prenat Diagn. May 1998;18(5):425-36. [Medline].

  10. Akiyama M, Suzumori K, Shimizu H. Prenatal diagnosis of harlequin ichthyosis by the examination of keratinized hair canals and amniotic fluid cells at 19 weeks' estimated gestational age. Prenat Diagn. Feb 1999;19(2):167-71. [Medline].

  11. Berg C, Geipel A, Kohl M, Krokowski M, Baschat AA, Germer U, et al. Prenatal sonographic features of Harlequin ichthyosis. Arch Gynecol Obstet. Apr 2003;268(1):48-51. [Medline].

  12. Bongain A, Benoit B, Ejnes L, Lambert JC, Gillet JY. Harlequin fetus: three-dimensional sonographic findings and new diagnostic approach. Ultrasound Obstet Gynecol. Jul 2002;20(1):82-5. [Medline].

  13. Watson WJ, Mabee LM Jr. Prenatal diagnosis of severe congenital ichthyosis (harlequin fetus) by ultrasonography. J Ultrasound Med. Mar 1995;14(3):241-3. [Medline].

  14. Chua CN, Ainsworth J. Ocular management of harlequin syndrome. Arch Ophthalmol. Mar 2001;119(3):454-5. [Medline].

  15. Haftek M, Cambazard F, Reano A. Harlequin foetus: a histological, ultrastructural and biochemical study of an etretinate-treated patient. Clin Exp Dermatol. 1989;14:393.

  16. Lacour M, Mehta-Nikhar B, Atherton DJ, Harper JI. An appraisal of acitretin therapy in children with inherited disorders of keratinization. Br J Dermatol. Jun 1996;134(6):1023-9. [Medline].

  17. Singh S, Bhura M, Maheshwari A, Kumar A, Singh CP, Pandey SS. Successful treatment of harlequin ichthyosis with acitretin. Int J Dermatol. Jul 2001;40(7):472-3. [Medline].

  18. Ripmeester P, Dunn S. Against all odds: breastfeeding a baby with harlequin ichthyosis. J Obstet Gynecol Neonatal Nurs. Sep-Oct 2002;31(5):521-5. [Medline].

  19. Thacher TD, Fischer PR, Pettifor JM, Darmstadt GL. Nutritional rickets in ichthyosis and response to calcipotriene. Pediatrics. Jul 2004;114(1):e119-23. [Medline].

  20. Chan YC, Tay YK, Tan LK, Happle R, Giam YC. Harlequin ichthyosis in association with hypothyroidism and juvenile rheumatoid arthritis. Pediatr Dermatol. Sep-Oct 2003;20(5):421-6. [Medline].

  21. Suzumori K, Kanzaki T. Prenatal diagnosis of harlequin ichthyosis by fetal skin biopsy; report of two cases. Prenat Diagn. Jul 1991;11(7):451-7. [Medline].

  22. Suresh S, Vijayalakshmi R, Indrani S, Lata M. Short foot length: a diagnostic pointer for harlequin ichthyosis. J Ultrasound Med. Dec 2004;23(12):1653-7. [Medline].

  23. Akiyama M. The pathogenesis of severe congenital ichthyosis of the neonate. J Dermatol Sci. Sep 1999;21(2):96-104. [Medline].

  24. Allen DM, Esterly NB. Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis. Arch Dermatol. Sep 2002;138(9):1259-60. [Medline].

  25. Ammirati CT, Mallory SB. The major inherited disorders of cornification. New advances in pathogenesis. Dermatol Clin. Jul 1998;16(3):497-508. [Medline].

  26. Dale BA, Holbrook KA, Fleckman P, Kimball JR, Brumbaugh S, Sybert VP. Heterogeneity in harlequin ichthyosis, an inborn error of epidermal keratinization: variable morphology and structural protein expression and a defect in lamellar granules. J Invest Dermatol. Jan 1990;94(1):6-18. [Medline].

  27. Dale BA, Kam E. Harlequin ichthyosis. Variability in expression and hypothesis for disease mechanism. Arch Dermatol. Nov 1993;129(11):1471-7. [Medline].

  28. DiGiovanna JJ. Ichthyosiform dermatoses. In: Fitzpatrick's Dermatology in General Medicine. 5th ed. New York, NY: McGraw-Hill; 1999:581-601.

  29. Fleck RM, Barnadas M, Schulz WW, Roberts LJ, Freeman RG. Harlequin ichthyosis: an ultrastructural study. J Am Acad Dermatol. Nov 1989;21(5 Pt 1):999-1006. [Medline].

  30. Gunes T, Akcakus M, Kurtoglu S, Cetin N, Karakükçü M. Harlequin baby with ecthyma gangrenosum. Pediatr Dermatol. Nov-Dec 2003;20(6):529-30. [Medline].

  31. Gånemo A, Sjöden PO, Johansson E, Vahlquist A, Lindberg M. Health-related quality of life among patients with ichthyosis. Eur J Dermatol. Jan-Feb 2004;14(1):61-6. [Medline].

  32. Haake AR, Holbrook K. The structure and development of skin. In: Fitzpatrick's Dermatology in General Medicine. New York, NY: McGraw-Hill; 1999:70-86.

  33. Hofmann B, Stege H, Ruzicka T, Lehmann P. Effect of topical tazarotene in the treatment of congenital ichthyoses. Br J Dermatol. Oct 1999;141(4):642-6. [Medline].

  34. Hovnanian A. Harlequin ichthyosis unmasked: a defect of lipid transport. J Clin Invest. Jul 2005;115(7):1708-10. [Medline].

  35. Prasad RS, Pejaver RK, Hassan A, al Dusari S, Wooldridge MA. Management and follow-up of harlequin siblings. Br J Dermatol. May 1994;130(5):650-3. [Medline].

  36. Roberts LJ. Long-term survival of a harlequin fetus. J Am Acad Dermatol. Aug 1989;21(2 Pt 2):335-9. [Medline].

  37. Unamuno P, Pierola JM, Fernandez E, Roman C, Velasco JA. Harlequin foetus in four siblings. Br J Dermatol. Apr 1987;116(4):569-72. [Medline].

Further Reading

Keywords

ichthyosis fetalis, harlequin ichthyosis, HI, harlequin baby, ichthyosis congenita, keratosis diffusa fetalis, harlequin fetus

Contributor Information and Disclosures

Author

Julie Prendiville, MB, BCh, Clinical Professor in Pediatrics, University of British Columbia; Head, Division of Pediatric Dermatology, British Columbia's Children's Hospital, Canada
Julie Prendiville, MB, BCh is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

Medical Editor

Abby S Van Voorhees, MD, Assistant Professor, Director of Psoriasis Services and Phototherapy Units, Department of Dermatology, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania
Abby S Van Voorhees, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, National Psoriasis Foundation, Phi Beta Kappa, Sigma Xi, and Women's Dermatologic Society
Disclosure: Amgen Honoraria Consulting; Astellas Grant/research funds Other; Abbott Honoraria Consulting; Genentech Honoraria Consulting; Incyte Grant/research funds Other; Centocor Honoraria Consulting; Warner Chilcott  Consulting; Merck Salary Review panel membership

Pharmacy Editor

Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University School of Medicine; Consulting Staff, Mountain View Dermatology, PA
Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, Texas Dermatological Society, and Texas Medical Association
Disclosure: Nothing to disclose.

Managing Editor

Van Perry, MD, Assistant Professor, Department of Medicine, Division of Dermatology, University of Texas Health Science Center
Van Perry, MD is a member of the following medical societies: American Academy of Dermatology and American Society for Laser Medicine and Surgery
Disclosure: Nothing to disclose.

CME Editor

Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology
Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds None; Genentech Consulting fee Consulting; Centocor Consulting fee Consulting; Centocor Grant/research funds None; Covance Consulting fee Consulting; Shire  Consulting

Chief Editor

William D James, MD, Paul R Gross Professor of Dermatology, University of Pennsylvania School of Medicine; Vice-Chair, Program Director, Department of Dermatology, University of Pennsylvania Health System
William D James, MD is a member of the following medical societies: American Academy of Dermatology and Society for Investigative Dermatology
Disclosure: elsevier Royalty Other; american college of physicians Honoraria Other

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.